COVID 19 caused by SARS-CoV-2 has spread across the globe claiming millions of life. However, many have survived after infection. There are multiple risk factors associated with the fatality of the disease like age, immunity, gender, diabetes, organ transplantation etc. Host immune response plays a critical role in control of infection and pathogenesis during this viral infection. Any treatment that modulate host immune response should be critically analysed before its implementation during this pandemic. Cancer patients receive systemic treatments to regress the tumor growth and have multiple side effects on host immune response. Little is known about the impact of such anticancer treatments on vulnerability, severity and mortality from COVID 19. This mini review focuses on the current literature and highlights the probable increase in risks for cancer patients receiving systemic anticancer treatments